AR049847A1 - POTASSIUM CHANNEL INHIBITORS - Google Patents
POTASSIUM CHANNEL INHIBITORSInfo
- Publication number
- AR049847A1 AR049847A1 ARP050102975A ARP050102975A AR049847A1 AR 049847 A1 AR049847 A1 AR 049847A1 AR P050102975 A ARP050102975 A AR P050102975A AR P050102975 A ARP050102975 A AR P050102975A AR 049847 A1 AR049847 A1 AR 049847A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- group
- independently
- heteroaryl
- heteroaryl ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
utiles como inhibidores del canal de potasio para tratar arritmias cardíacas y afecciones similares. Reivindicacion 1: Un compuesto de formula (1), o una de sus sales farmacéuticamente aceptables, que tiene la formula (1), en la que: A, B y C se seleccionan independientemente del grupo consistente en: a) un anillo arilo; y b) un anillo heteroarilo, en el que el punto de union al anillo heteroarilo es un átomo de carbono y el anillo heteroarilo se selecciona del grupo consistente en: b1) un anillo monocíclico no saturado de 5 miembros con 1, 2, 3 o 4 átomos de anillo heteroátomos seleccionados del grupo consistente en N, O u S; b2) un anillo monocíclico no saturado de 6 miembros con 1, 2, 3 o 4 átomos de anillo heteroátomos seleccionados del grupo consistente en N, O u S; y c) un anillo bicíclico no saturado de 8-9- o 10 miembros con 1, 2, 3 o 4 átomos de anillo heteroátomos seleccionados del grupo consistente en N, O u S; dicho anillo arilo y heteroarilo está no sustituido, monosustituido con R4, disustituido con grupos seleccionados independientemente de R4, trisustituido con grupos seleccionados independientemente de R4, o tetrasustituido con grupos seleccionados independientemente de R4, y en el que cualquier átomo de anillo heteroarilo o heterocíclico S o N estable está no sustituido o está sustituido con oxo, estando dichas sustituciones R4 del anillo heteroarilo en uno o más átomos de carbono del anillo heteroarilo; con la condicion de que al menos uno de los sustituyentes A, B y C es un anillo heteroarilo; D se selecciona del grupo consistente en: a) un anillo arilo; b) un anillo heteroarilo, en el que el punto de union al anillo heteroarilo es un átomo de carbono, y el anillo heteroarilo se selecciona del grupo consistente en: b1) un anillo monocíclico no saturado de 5 miembros con 1, 2, 3 o 4 átomos de anillo heteroátomos seleccionados del grupo consistente en N, O u S; b2) un anillo monocíclico no saturado de 6 miembros con 1, 2, 3 o 4 átomos de anillo heteroátomos seleccionados del grupo consistente en N, O u S; y c) un anillo bicíclico no saturado de 8-9- o 10 miembros con 1, 2, 3 o 4 átomos de anillo heteroátomos seleccionados del grupo consistente en N, O u S; y c) un anillo heterocíclico saturado de 4 a 6 miembros con 1, 2 o 3 átomos de anillo heteroátomos seleccionados del grupo consistente en N, O y S, en el que el punto de union del anillo heterocíclico es un átomo de carbono; estando dicho anillo arilo, heteroarilo, heterocíclico saturado no sustituido, monosustituido con R4, disustituido con grupos seleccionados independientemente de R4, trisustituidos con grupos seleccionados independientemente de R4, o tetrasustituidos con grupos seleccionados independientemente de R4, y en el que cualquier átomo de anillo heteroarilo o heterocíclico S o N estable está no sustituido o está sustituido con oxo, estando dichas sustituciones R4 de anillo heteroarilo en uno o más átomos de carbono del anillo heteroarilo; X e Y se seleccionan independientemente del grupo consistente en H y OR5; Ra, en cada caso en el que aparece, se selecciona independientemente del grupo consistente en hidrogeno, alquilo C1-6 y halogeno; R4, en cada caso en el que aparece, se selecciona independientemente del grupo consistente en hidrogeno, halogeno, CN, CR4=C(R5)2, (CRa2)nOR5, (CRa2)nN(R5)2, (CRa2)nC(O)R5, N(R5)C(O)R5, C(O)OR5 y N(R5)S(O)mR5; R5, en cada caso en el que aparece, se selecciona independientemente del grupo consistente en hidrogeno, alquilo C1-6 no sustituido o sustituido, cicloalquilo C3-10 no sustituido o sustituido, arilo no sustituido o sustituido y heterociclilo no sustituido o sustituido; m es, de forma independiente, 0,1 o 2; y n es, de forma independiente, 0, 1, 2, 3, 4, 5 o 6.Useful as potassium channel inhibitors to treat cardiac arrhythmias and similar conditions. Claim 1: A compound of formula (1), or a pharmaceutically acceptable salt thereof, having formula (1), wherein: A, B and C are independently selected from the group consisting of: a) an aryl ring; and b) a heteroaryl ring, wherein the point of attachment to the heteroaryl ring is a carbon atom and the heteroaryl ring is selected from the group consisting of: b1) a 5-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting of N, O or S; b2) a 6-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting of N, O or S; and c) an unsaturated 8-9- or 10-membered bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting of N, O or S; said aryl and heteroaryl ring is unsubstituted, monosubstituted with R4, disubstituted with groups selected independently of R4, trisubstituted with groups selected independently of R4, or tetrasubstituted with groups selected independently of R4, and wherein any heteroaryl or heterocyclic ring atom S or stable N is unsubstituted or substituted with oxo, said R4 substitutions of the heteroaryl ring being one or more carbon atoms of the heteroaryl ring; with the proviso that at least one of the substituents A, B and C is a heteroaryl ring; D is selected from the group consisting of: a) an aryl ring; b) a heteroaryl ring, in which the point of attachment to the heteroaryl ring is a carbon atom, and the heteroaryl ring is selected from the group consisting of: b1) a 5-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting of N, O or S; b2) a 6-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting of N, O or S; and c) an unsaturated 8-9- or 10-membered bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting of N, O or S; and c) a 4 to 6-membered saturated heterocyclic ring with 1, 2 or 3 heteroatom ring atoms selected from the group consisting of N, O and S, wherein the point of attachment of the heterocyclic ring is a carbon atom; said aryl, heteroaryl, unsaturated saturated heterocyclic ring being monosubstituted with R4, disubstituted with groups independently selected from R4, trisubstituted with groups independently selected from R4, or tetrasubstituted with groups selected independently from R4, and wherein any heteroaryl ring atom or stable S or N heterocyclic is unsubstituted or substituted with oxo, said R4 substitutions of heteroaryl ring being at one or more carbon atoms of the heteroaryl ring; X and Y are independently selected from the group consisting of H and OR5; Ra, in each case in which it appears, is independently selected from the group consisting of hydrogen, C1-6 alkyl and halogen; R4, in each case in which it appears, is independently selected from the group consisting of hydrogen, halogen, CN, CR4 = C (R5) 2, (CRa2) nOR5, (CRa2) nN (R5) 2, (CRa2) nC ( O) R5, N (R5) C (O) R5, C (O) OR5 and N (R5) S (O) mR5; R5, in each case in which it appears, is independently selected from the group consisting of hydrogen, unsubstituted or substituted C1-6 alkyl, unsubstituted or substituted C3-10 cycloalkyl, unsubstituted or substituted aryl and unsubstituted or substituted heterocyclyl; m is, independently, 0.1 or 2; and n is, independently, 0, 1, 2, 3, 4, 5 or 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59218104P | 2004-07-29 | 2004-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049847A1 true AR049847A1 (en) | 2006-09-06 |
Family
ID=35613661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102975A AR049847A1 (en) | 2004-07-29 | 2005-07-19 | POTASSIUM CHANNEL INHIBITORS |
Country Status (15)
| Country | Link |
|---|---|
| KR (1) | KR20070043985A (en) |
| AR (1) | AR049847A1 (en) |
| BR (1) | BRPI0513793A (en) |
| CR (1) | CR8876A (en) |
| EC (1) | ECSP077208A (en) |
| IL (1) | IL180846A0 (en) |
| MA (1) | MA28980B1 (en) |
| MX (1) | MX2007001188A (en) |
| NO (1) | NO20071107L (en) |
| PE (1) | PE20060382A1 (en) |
| RU (1) | RU2344134C2 (en) |
| TW (1) | TW200607493A (en) |
| UA (1) | UA88018C2 (en) |
| WO (1) | WO2006028590A1 (en) |
| ZA (1) | ZA200700477B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2755569A1 (en) * | 2009-03-18 | 2010-09-23 | Medicure International Inc. | Transdermal pharmaceutical preparation and administration of tirofiban |
| SI2858987T1 (en) | 2012-06-11 | 2018-06-29 | Bristol-Myers Squibb Company | Phosphoramidic acid prodrugs of 5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4394451B2 (en) * | 2002-01-04 | 2010-01-06 | ニューロサーチ、アクティーゼルスカブ | Potassium channel modulator |
-
2005
- 2005-07-19 AR ARP050102975A patent/AR049847A1/en unknown
- 2005-07-22 TW TW094125011A patent/TW200607493A/en unknown
- 2005-07-22 PE PE2005000858A patent/PE20060382A1/en not_active Application Discontinuation
- 2005-07-25 KR KR1020077002228A patent/KR20070043985A/en not_active Application Discontinuation
- 2005-07-25 UA UAA200702125A patent/UA88018C2/en unknown
- 2005-07-25 MX MX2007001188A patent/MX2007001188A/en unknown
- 2005-07-25 WO PCT/US2005/026334 patent/WO2006028590A1/en active Application Filing
- 2005-07-25 RU RU2007107408/04A patent/RU2344134C2/en not_active IP Right Cessation
- 2005-07-25 BR BRPI0513793-4A patent/BRPI0513793A/en not_active IP Right Cessation
-
2007
- 2007-01-16 ZA ZA200700477A patent/ZA200700477B/en unknown
- 2007-01-21 IL IL180846A patent/IL180846A0/en unknown
- 2007-01-25 CR CR8876A patent/CR8876A/en not_active Application Discontinuation
- 2007-01-26 EC EC2007007208A patent/ECSP077208A/en unknown
- 2007-02-21 MA MA29689A patent/MA28980B1/en unknown
- 2007-02-27 NO NO20071107A patent/NO20071107L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0513793A (en) | 2008-05-13 |
| WO2006028590A1 (en) | 2006-03-16 |
| ZA200700477B (en) | 2009-08-26 |
| CR8876A (en) | 2007-08-28 |
| RU2007107408A (en) | 2008-09-10 |
| NO20071107L (en) | 2007-04-19 |
| MA28980B1 (en) | 2007-11-01 |
| RU2344134C2 (en) | 2009-01-20 |
| MX2007001188A (en) | 2007-03-21 |
| UA88018C2 (en) | 2009-09-10 |
| KR20070043985A (en) | 2007-04-26 |
| ECSP077208A (en) | 2007-02-28 |
| TW200607493A (en) | 2006-03-01 |
| PE20060382A1 (en) | 2006-05-15 |
| IL180846A0 (en) | 2007-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122821T1 (en) | 1,3-BENZODIOXOLE DERIVATIVES AS EZE1 AND/OR EZE2 INHIBITORS | |
| PE20190656A1 (en) | TIAZOLO-PYRIDINE COMPOUNDS REPLACED AS INHIBITORS OF MALT1 | |
| AR100645A1 (en) | PYRAZOLO-PYRIMIDINE DERIVATIVES | |
| EA201890594A1 (en) | Aryl, Heteroaryl, and Heterocyclic Compounds for the Treatment of Disorders | |
| PE20161405A1 (en) | CORTISTATIN ANALOGS AND SYNTHESIS AND USES OF THE SAME | |
| PE20171177A1 (en) | JAK INHIBITING AMINOPYRIMIDINYL COMPOUNDS | |
| ECSP055987A (en) | HETEROARILCARBAMOILBENCENO DERIVATIVES | |
| AR093144A2 (en) | VIRAL POLYMERASE INHIBITORS | |
| AR088449A1 (en) | BENZILINDAZOLES REPLACED | |
| PE20161443A1 (en) | COMPOUNDS | |
| AR048778A1 (en) | PIRROLIDINYL DERIVATIVES AS INHIBITORS OF 11-BETA HYDROXIESTEROID DEHYDROGENASE | |
| AR088829A1 (en) | CYCLHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC B2 AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS | |
| PE20181144A1 (en) | HETEROARYL DERIVATIVES AS PARP INHIBITORS | |
| EA201000101A1 (en) | DERIVATIVES OF PYRIMIDINE 934 | |
| AR072166A1 (en) | PIPERIDINE DERIVATIVE AND ITS USE AS A SUPERIOR RENINA INHIBITOR | |
| PE20191020A1 (en) | CHEMICAL COMPOUNDS | |
| CY1124795T1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF SURGICAL SITE INFECTIONS | |
| CY1125004T1 (en) | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA | |
| AR113842A1 (en) | THIAZOL DERIVATIVES MICROBIOCIDES | |
| PE20190979A1 (en) | HETEROARILCARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | |
| CO2018010787A2 (en) | Griseofulvin compound | |
| UY32632A (en) | DERIVATIVES OF CICLOPENTA [C] PIRROLILALQUILCARBAMATOS OF HETEROCICLOS OF 5 MEMBERS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. | |
| AR111814A1 (en) | USEFUL FORMIMIDAMIDE COMPOUNDS AGAINST PHYTOOPATHOGEN MICROORGANISMS | |
| AR096040A1 (en) | SUBSTITUTED AND CONDENSED PIRIMIDINE COMPOUNDS AS PDE4B INHIBITORS | |
| CL2018000356A1 (en) | Substituted 1,2-dihydro-3h-pyrrolo [1,2-c] imidazol-3-one antibacterial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |